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We applaud Dryden and Mactier for their extensive analysis of maternal factors in opiate-addicted women which place their infants at risk for severe neonatal abstinence syndrome (NAS) requiring pharmacologic treatment. The intent of our study was to assess factors associated with response to a specified pharmacotherapy protocol for NAS. Determining the incidence of NAS at our institution was outside of the scope of our study. It is reassuring that where our works overlapped, we came to similar conclusions. We were remiss in not citing their work and appreciate the opportunity to clarify some of our methodology and results.
The differences between the standards of care of infants with NAS at our institution and those of Dryden and Mactier may help to explain some of the questions and concerns expressed in their Letter to the Editor. At our hospital, mothers are often discharged after 48 h of vaginal delivery or after 72 h following delivery by cesarean section. In contrast, Dryden and Mactier reported that mothers are able to room-in with their infants for up to 10 days. (This ability to treat the infant in the presence of the mother, maintaining the physical maternal-infant bonding, is highly desirable and these services are commendable.)
After a mother is discharged from our hospital, she is highly encouraged to provide expressed human milk to the hospital for subsequent bottle feedings for her infant in her absence. However, logistical problems such as transportation, care of older children and the demands of her own medical care encumber these mothers and serve as impediments to visiting. Most of the feedings of infants being treated for NAS at our institution, therefore, is either expressed mother's milk or formula. The calculation of the proportion of human milk intake was derived from the exact volume of expressed mother's milk fed to the infants, and could easily be abstracted from the flowsheet. In the uncommon event that a mother visited her infant and elected to feed directly at the breast, the determination of proportion of total intake comprising of maternal breast milk was a ratio of the number of breast feedings plus subsequent expressed-bottle feedings, divided by the total number of feedings for the day. The identification of rebound withdrawal symptoms, which occurred in infants from our study whose human milk intake was abruptly weaned, may have been obfuscated in the study by Dryden and Mactier due to the lower incidence of breast feeding at the time of discharge. They did report three infants who were started on phenobarbital therapy after being discharged home, but it is unclear whether these infants were on mother's milk at the time of discharge. We agree that further work is needed to identify infants at risk for rebound NAS.
We understand the caution by Dryden and Mactier regarding the use of length-of-stay as a proxy for NAS severity, particularly when pre-term infants are included in the sample set. However, at our institution, discharge planning begins at the time of admission. The goal is to have the social aspects of disposition completed by the time the infant's clinical problems are resolved. It is unusual that questions pertaining to disposition would extend an infant's hospitalization by more than a day. Therefore, we feel confident that the length-of-stay predictably coincides with days of pharmacotherapy at our institution, and this was the rationale for its use as a reflection of the severity of NAS. Our data confirm this as the length-of-stay in term infants (mean 17.3 days) roughly equates to the duration of methadone therapy (mean 12.4 days), plus the age at initiation (mean 1.8 days), plus the protocolmandated 2-day observation after cessation of methadone pharmacotherapy. Incidentally, the mean duration of methadone therapy in term infants in our study is only 1 day longer than was reported by Dryden and Mactier in their experience with morphine, which they rightly point out, is a shorter acting agent, and infant's response to tapering of the dose would be expected to occur more readily. However, with most of our NAS population receiving methadone through mother's milk, our preference is to maintain methadone as first-line monotherapy in treating infants with NAS.
Finally, our conclusions that the requirements for opiate therapy in pre-term infants is less than we observed in term infants strictly refers to the more rapid tapering of the methadone protocol in infants requiring pharmacotherapy for NAS. We appreciate the interest expressed by Dryden and Mactier, and the opportunity for clarification of our report. Their study and ours complement each other in several ways, and we believe that together we have both contributed in moving the field forward.
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